1
The vaccine could be created as a ready-to-use product, rather than needing to be personalised
ErVimmune, a preclinical biotechnology company focused on the development of cell therapies and cancer vaccines, has announced a total of 17m euros in new funding, allowing it to advance its cancer vaccine candidate.
The company’s lead candidate, ErVac01, is a heterologous vaccine formulation containing a collection of human endogenous retrovirus (HERV)-derived epitopes, designed to cover the majority of the worldwide population in terms of HLA alleles. The selection of antigens shared across…